AHK (Tripeptide-3)
Signaling Tripeptide
Overview
AHK is a three-amino-acid peptide — alanine, histidine, and lysine, in that sequence — that researchers have studied for its ability to activate collagen-related gene expression in dermal fibroblasts. The mechanism involves TGF-β (transforming growth factor-beta) signaling, one of the primary pathways your skin uses to regulate how much collagen and extracellular matrix it produces. That's a meaningful target. Collagen loss is one of the central drivers of skin aging, and most topical approaches don't reach the fibroblasts where that production actually happens.
Mechanism of Action
TGF-β pathway activation; antioxidant signaling; extracellular matrix gene upregulation
What the Evidence Shows
The honest summary: AHK's evidence base is preclinical. That means cell cultures and, to a limited extent, animal models — not human trials.
In-vitro studies using human dermal fibroblast cultures have been proposed to show that AHK may stimulate upregulation of extracellular matrix genes including those encoding collagen types I and III, though peer-reviewed evidence in primary literature is not currently available.[1] These are controlled laboratory conditions, not skin. Cell culture results frequently don't replicate in intact tissue, let alone in clinical outcomes — a distinction that matters when evaluating any topical peptide.
The copper-chelated form, AHK-Cu, has been studied alongside GHK-Cu in some research contexts. GHK-Cu has a more developed evidence base, including a small number of human studies showing improvements in skin thickness and collagen density with topical application.[2] AHK-Cu is often positioned as a complementary compound, but direct human data for AHK-Cu specifically is limited — practitioner-reported, not confirmed in published clinical trials.
No registered clinical trials for AHK or AHK-Cu appear on ClinicalTrials.gov — AHK (Tripeptide-3) remains a research-only compound with no established clinical dosing or human safety data as of March 2026. No peer-reviewed Phase 1, 2, or 3 trial results in human subjects have been published.